A double-blind, randomized, placebo-controlled trial of oral isotretinoin in the treatment of recalcitrant facial flat warts

Olguín-García, M.G.; Cruz, Fermín Jurado-Santa; Peralta‐Pedrero, María Luisa; Morales‐Sánchez, Martha Alejandra

doi:10.3109/09546634.2013.869302

Cited by 37 publications

(46 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vitamin A treatment may also increase or prolong expression of HPV T or B cell antigens, allowing clearance of warts by immune mechanisms . Our results support the previous findings that oral retinoids including acitretin and isotretinoin have been used with marked improvement in the management of extensive and recalcitrant warts . Additionally, retinol possesses antioxidant activities .…”

Section: Discussionsupporting

confidence: 89%

“…5 Our results support the previous findings that oral retinoids including acitretin and isotretinoin have been used with marked improvement in the management of extensive and recalcitrant warts. [18][19][20][21][22] Additionally, retinol possesses antioxidant activities. 23 Micronutrient deficiencies, especially zinc deficiency that is commonly reported in recalcitrant warts patients, 24 reduces circulating retinol, causing a functional vitamin A deficiency even with sufficient liver stores.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum retinol‐binding protein: a novel biomarker for recalcitrant cutaneous warts

2019

View full text Add to dashboard Cite

Background Cutaneous viral warts are benign epidermal proliferations caused by human papillomaviruses (HPVs). Despite treatment, a significant proportion of warts fail to resolve, becoming recalcitrant. Vitamin A (retinol) may disrupt the interplay of HPV replication and epithelial cell differentiation, allowing normal tissue to replace warts. Circulating retinol‐binding protein (RBP) concentrations highly correlate with retinol levels. Aim We aimed at evaluation of serum RBP level in patients with recalcitrant cutaneous warts in order to assess its correlation with disease pathogenesis. Methods Serum RBP level was measured by an ELISA technique in 50 patients with recalcitrant cutaneous warts and 30 apparently healthy controls. Results Serum RBP level was significantly lower in patients with recalcitrant warts than the control group (P < 0.001). However, it did not differ regarding different clinical parameters in studied patients (P > 0.05 each). RBP is a reliable biomarker for significant early detection and discrimination between patients and healthy controls (P < 0.001) at a cutoff value ≤1034.6 μg/ml, with sensitivity and specificity (100% each). Conclusion Our results revealed that low serum RBP as a relatively cheap biomarker with high specificity and sensitivity is a reliable indicator of vitamin A (retinol) deficiency that may play a role in the pathogenesis of recalcitrant cutaneous warts among our studied patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Serum retinol‐binding protein: a novel biomarker for recalcitrant cutaneous warts

2019

View full text Add to dashboard Cite

show abstract

“…studied the effect of oral isotretinoin in facial flat warts and concluded that all patients in the oral isotretinoin group showed complete clearance, whereas none in the placebo group showed any improvement. The most frequent side effect was cheilitis …”

Section: Discussionmentioning

confidence: 99%

Evaluation of the efficacy and safety of oral isotretinoin versus topical isotretinoin in the treatment of plane warts: a randomized open trial

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It has recently been reported that the topical proprietary formulation consisting of 1% cantharidin, 5% podophyllotoxin, and 30% salicylic acid (CPS) has achieved complete clearance of RPW in 100% of patients . This is a high cure rate compared to other treatments but it's a preliminary study. Despite its regular clinical use and reported safety , inadequate data currently exist to modify the FDA status of cantharidin or reassure institutions of its safety .…”

Section: Introductionmentioning

confidence: 94%

Safety and effectiveness of cantharidin-podophylotoxin-salicylic acid in the treatment of recalcitrant plantar warts

López‐López

Fernández

Iglesias

et al. 2016

Dermatologic Therapy

View full text Add to dashboard Cite

The aim of our study was to evaluate the efficacy and safety of topical cantharidin-podophylotoxin-salicylic acid (CPS) treatment of recalcitrant plantar warts (RPW). This study was carried out in a health center in the city of A Coruña (Spain) between January and December 2013. A total of 75 patients completed all the stages of the research process. Information related to treatment with CPS and adverse effects was abstracted from medical records. Of 93 potential patients identified, 75 had at least one follow-up visit or telephone call after treatment and were included in this study. Patients experienced an average of 5.4 visits until complete resolution of their plantar wart occurred, although CPS was not applied at every visit. Fifty-four patients required one application to eliminate the wart and 21 patients required two applications/patient. Seventy-seven percent of patients experienced blistering - an expected therapeutic side effect. All patients experienced some form of an adverse event, the most common being pain (81.3%) and significant blistering (15%). Other side effects were rare (18.7%) and included pruritus, possible mild infection, significant irritation, and bleeding. All patients reported treatment, supporting our results that CPS is a safe and efficacious treatment modality for RPW and should be considered when symptomatic infection necessitates treatment.

show abstract

A double-blind, randomized, placebo-controlled trial of oral isotretinoin in the treatment of recalcitrant facial flat warts

Abstract: Isotretinoin is an effective treatment for recalcitrant flat facial warts with a well-known, manageable safety profile.

Cited by 37 publications

References 17 publications

Serum retinol‐binding protein: a novel biomarker for recalcitrant cutaneous warts

Serum retinol‐binding protein: a novel biomarker for recalcitrant cutaneous warts

Evaluation of the efficacy and safety of oral isotretinoin versus topical isotretinoin in the treatment of plane warts: a randomized open trial

Safety and effectiveness of cantharidin-podophylotoxin-salicylic acid in the treatment of recalcitrant plantar warts

Contact Info

Product

Resources

About